$5.30−0.20 (−3.64%)
At close: Nov 18, 2026, 4:00 PM ET· Nasdaq · USD
Phathom Pharmaceuticals (PHAT) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~1502.4%/yr (FY23→FY25), net margin −126.3%. Worth your attention in FY25: Share count (+97.1%) and Capex step-up ($229.0K). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲216.9%
175.1
FY21→FY25CAGR —
Net income ($M)▲33.8%
−221.2
FY21→FY25CAGR —
Free cash flow ($M)▲37.4%
−167.0
capex stepped upCAGR —
Diluted EPS▲42.7%
−3.03
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+97.1%
37.0mn → 72.9mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex step-up
$229.0K
▲70% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-126¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Net margin -126.3% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 274,881.0 | 175,110.0 | 55,252.0 | 682.0 | 0.0 | 0.0 | ▲216.9% | — |
Cost of revenue | 53,106.0 | 22,599.0 | 7,973.0 | 167.0 | 0.0 | 0.0 | ▲183.4% | — |
Gross profit | 221,775.0 | 152,511.0 | 47,279.0 | 515.0 | 0.0 | 0.0 | ▲222.6% | — |
Research & development | 31,822.0 | 32,780.0 | 34,082.0 | 49,899.0 | 71,441.0 | 72,338.0 | ▼3.8% | −18.0% |
Selling, general & admin | 215,408.0 | 279,717.0 | 290,664.0 | 117,928.0 | 100,999.0 | 62,742.0 | ▼3.8% | +45.3% |
Total operating expenses | 247,230.0 | 312,497.0 | 324,746.0 | 167,827.0 | 172,440.0 | 135,080.0 | ▼3.8% | +23.3% |
Operating incomefeeds ROC rank | −25,455.0 | −159,986.0 | −277,467.0 | −167,312.0 | −172,440.0 | −135,080.0 | ▲42.3% | — |
Other income, net | −57,541.0 | −61,261.0 | −56,859.0 | −34,280.0 | −25,283.0 | −8,803.0 | — | — |
Pretax income | −82,996.0 | −221,247.0 | −334,326.0 | −201,592.0 | −197,723.0 | −143,883.0 | ▲33.8% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −82,996.0 | −221,247.0 | −334,326.0 | −201,592.0 | −197,723.0 | −143,883.0 | ▲33.8% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −1.00 | −3.03 | −5.29 | −3.93 | −5.05 | −3.89 | ▲42.7% | — |
Diluted shares (mn) | 84.89 | 72.92 | 63.18 | 51.29 | 39.12 | 37.00 | ▲15.4% | +18.5% |
| Margins | ||||||||
Gross margin75th pct in Healthcare | 80.7% | 87.1% | 85.6% | 75.5% | — | — | ▲1.5pp | +11.6pp |
Operating margin | −9.3% | −91.4% | −502.2% | −24532.6% | — | — | ▲410.8pp | +24441.2pp |
Net margin19th pct in Healthcare | −30.2% | −126.3% | −605.1% | −29558.9% | — | — | ▲478.7pp | +29432.6pp |
† TTM = trailing four quarters through 2026-09-30.
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Phathom Pharmaceuticals' revenue last fiscal year?
Phathom Pharmaceuticals reported revenue of $175.1M in fiscal 2025, up 216.9% from fiscal 2024.
What was Phathom Pharmaceuticals' net income?
Phathom Pharmaceuticals reported net income of −$221.2M in fiscal 2025, a net margin of −126.3%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

